Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Fitchett

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Circulation|September 17, 2014
Cardiology Patient Page: coronary artery revascularization in patients with diabetes mellitusDavid H Fitchett, Milan Gupta, Michael E Farkouh, et al.
The Canadian Journal of Cardiology|September 8, 2006
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patientsDavid H Fitchett, Lawrence A Leiter, Shaun G Goodman, et al.
The Canadian Journal of Cardiology|June 3, 2014
Risk stratification and selection for statin therapy: going beyond FraminghamDavid H Fitchett, G B John Mancini, Jean Gregoire, et al.
The Canadian Journal of Cardiology|February 3, 2005
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?David H Fitchett, Lawrence A Leiter, Jean-Claude Tardif, et al.
The Canadian Journal of Cardiology|May 28, 2008
Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes?J Malcolm Arnold, David H Fitchett, Jonathan G Howlett, et al.
American Heart Journal|January 31, 2006
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trialDavid H Fitchett, Anatoly Langer, Paul W Armstrong, et al.
Circulation|July 30, 2016
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical ApplicationsHiddo J L Heerspink, Bruce A Perkins, David H Fitchett, et al.
Canadian Family Physician Medecin De Famille Canadien|May 23, 2012
Managing cardiometabolic risk in primary care: summary of the 2011 consensus statementAnanda Chatterjee, Stewart B Harris, Lawrence A Leiter, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 29, 2006
Bedtime administration of graded-release diltiazem in patients with inadequate BP control: a tolerability and efficacy studyDavid H Fitchett, Amparo Casanova, Shahin Jaffer, et al.
American Heart Journal|March 27, 2007
Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndromeAndrew T Yan, Raymond T Yan, Mary Tan, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Circulation|September 17, 2014
Cardiology Patient Page: coronary artery revascularization in patients with diabetes mellitusDavid H Fitchett, Milan Gupta, Michael E Farkouh, et al.
The Canadian Journal of Cardiology|September 8, 2006
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patientsDavid H Fitchett, Lawrence A Leiter, Shaun G Goodman, et al.
The Canadian Journal of Cardiology|June 3, 2014
Risk stratification and selection for statin therapy: going beyond FraminghamDavid H Fitchett, G B John Mancini, Jean Gregoire, et al.
The Canadian Journal of Cardiology|February 3, 2005
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?David H Fitchett, Lawrence A Leiter, Jean-Claude Tardif, et al.
The Canadian Journal of Cardiology|May 28, 2008
Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes?J Malcolm Arnold, David H Fitchett, Jonathan G Howlett, et al.
American Heart Journal|January 31, 2006
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trialDavid H Fitchett, Anatoly Langer, Paul W Armstrong, et al.
Circulation|July 30, 2016
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical ApplicationsHiddo J L Heerspink, Bruce A Perkins, David H Fitchett, et al.
Canadian Family Physician Medecin De Famille Canadien|May 23, 2012
Managing cardiometabolic risk in primary care: summary of the 2011 consensus statementAnanda Chatterjee, Stewart B Harris, Lawrence A Leiter, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 29, 2006
Bedtime administration of graded-release diltiazem in patients with inadequate BP control: a tolerability and efficacy studyDavid H Fitchett, Amparo Casanova, Shahin Jaffer, et al.
American Heart Journal|March 27, 2007
Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndromeAndrew T Yan, Raymond T Yan, Mary Tan, et al.
Pageof 6